可待因,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
1116	*40	The CYP2D640 allele is assigned as a no function allele by CPIC. Patients carrying the 40 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *40 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.
1115	*17	The CYP2D617 allele is assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the 17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.
1114	*6	The CYP2D66 allele is assigned as a no function allele by CPIC. Patients carrying the 6 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.
1113	*5	The CYP2D65 allele is assigned as a no function allele by CPIC. Patients carrying the 5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.
1112	*4	The CYP2D64 allele is assigned as a no function allele by CPIC. Patients carrying the 4 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.
1111	*1	The CYP2D61 allele is assigned as a normal function allele by CPIC. Patients carrying the 1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar analgesic response to codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have a similar analgesic response to codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but an increased analgesic response to codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

等位基因

注释文本

The CYP2D6*40 allele is assigned as a no function allele by CPIC. Patients carrying the *40 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *40 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

1115

*17

The CYP2D6*17 allele is assigned as a decreased function allele with an activity score of 0.5 by CPIC. Patients carrying the *17 allele in combination with a decreased or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype, while patients carrying the *17 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

1114

The CYP2D6*6 allele is assigned as a no function allele by CPIC. Patients carrying the *6 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *6 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

1113

The CYP2D6*5 allele is assigned as a no function allele by CPIC. Patients carrying the *5 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *5 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

1112

The CYP2D6*4 allele is assigned as a no function allele by CPIC. Patients carrying the *4 allele in combination with a decreased, normal or no function allele may have a decreased analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Patients carrying the *4 allele in combination with an increased function allele may have a similar analgesic response when treated with codeine as compared to patients with alleles that result in a normal metabolizer phenotype. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

1111

The CYP2D6*1 allele is assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may have a similar analgesic response to codeine as compared to patients carrying two increased function alleles or an increased function allele in combination with a normal function allele or a decreased function allele with an activity value of 0.5. Patients carrying the *1 allele in combination with alleles that result in a normal metabolizer phenotype may also have a similar analgesic response to codeine as compared to patients carrying an increased function allele with an activity value of 3 or greater in combination with a no function allele or a decreased function allele with an activity value of 0.25 but an increased analgesic response to codeine as compared to patients with a no function allele in combination with a decreased or normal function allele or two decreased or no function alleles. Other genetic and clinical factors may also influence analgesic response when treated with codeine.

id	证据的ID	总结
205	1183632376	CYP2D6 4/4 + 4/5 is associated with decreased analgesia from codeine for postpartum pain management when treated with codeine in women as compared to CYP2D6 1/1.
204	1183617920	CYP2D6 4/6 is associated with intolerance to codeine ( significant side effects as well as no pain relief) when treated with codeine.
203	982046937	CYP2D6 40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 1.
202	982046931	CYP2D6 17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 1.
201	982046919	CYP2D6 5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 1.
200	982046905	CYP2D6 4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 1.
199	1451645100	CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.
198	1451404282	CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to codeine in people with Pain as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.
197	1451351660	CYP2D6 normal metabolizers are associated with increased response to codeine in people with Pain as compared to CYP2D6 poor metabolizers and intermediate metabolizers.
196	1450376074	CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.
195	PA166104970	Annotation of DPWG Guideline for codeine and CYP2D6
194	PA166104996	Annotation of CPIC Guideline for codeine and CYP2D6

证据的ID

总结

205

1183632376

CYP2D6 *4/*4 + *4/*5 is associated with decreased analgesia from codeine for postpartum pain management when treated with codeine in women as compared to CYP2D6 *1/*1.

204

1183617920

CYP2D6 *4/*6 is associated with intolerance to codeine ( significant side effects as well as no pain relief) when treated with codeine.

203

982046937

CYP2D6 *40 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.

202

982046931

CYP2D6 *17 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.

201

982046919

CYP2D6 *5 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.

200

982046905

CYP2D6 *4 is associated with decreased response to codeine in children with Anemia, Sickle Cell as compared to CYP2D6 *1.

199

1451645100

CYP2D6 poor metabolizers and intermediate metabolizers are associated with decreased response to codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone or tramadol in people with Neoplasms and Pain as compared to CYP2D6 normal metabolizers.

198

1451404282

CYP2D6 poor metabolizer and intermediate metabolizer genotypes are associated with decreased response to codeine in people with Pain as compared to CYP2D6 normal metabolizer and ultrarapid metabolizer genotypes.

197

1451351660

CYP2D6 normal metabolizers are associated with increased response to codeine in people with Pain as compared to CYP2D6 poor metabolizers and intermediate metabolizers.

196

1450376074

CYP2D6 poor metabolizer is associated with increased likelihood of Pain when treated with codeine or tramadol in people with Pain as compared to CYP2D6 normal metabolizer.

195

PA166104970

Annotation of DPWG Guideline for codeine and CYP2D6

194

PA166104996

Annotation of CPIC Guideline for codeine and CYP2D6

id	类型	评论
1600	Update	Added PMID 34423496 to evidence.
1599	Update	Added DPWG guideline as evidence
1598	Update	Added PMID 33750887 to evidence
1597	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1596	Update	Added PMID 31141989 to evidence
1595	Update	Minor edits to phenotype descriptions
1594	Update	Minor edits to phenotype descriptions
1593	Create	Created